[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ovulation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ovulation":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,56,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100628788","phase-4-exogenous-progesterone-as-ovulation-trigger-100628788",false,"NCT07466199","Exogenous Progesterone as Ovulation Trigger","Exogenous Progesterone as Ovulation Trigger - a Pilot Study","PRO-TRIGGER","Inclusion Criteria:\n\n* Informed Consent Form dated and signed correctly prior to the performance of any study procedure.\n* Oocyte donors aged \\>17 and \\\u003C34 years old in the moment of the recruitment.\n* Patients with regular menstrual cycles (between 25 to 35 days long).\n* Generally healthy women with no history of endocrine disorders (e.g., polycystic ovary syndrome (PCOS) or significant systemic disease).\n* Body Mass Index (BMI) between 18.5 and 28.\n\nExclusion Criteria:\n\n* Presence of ovarian cyst(s) detected on the baseline (initial) ultrasound examination.\n* Untreated endocrine conditions (polycystic ovary syndrome (PCOS), uncontrolled thyroid dysfunction and hyperprolactinemia).\n* Hypogonadotropic or hypergonadotropic hypogonadism.\n* Known hypersensitivity or clinical contraindication to the administration of vaginal progesterone or its excipients. This includes, but is not limited to: active deep vein thrombosis or thromboembolic disorders, known or suspected estrogen- or progesterone-dependent neoplasia, undiagnosed abnormal genital bleeding, porphyria, or severe hepatic dysfunction. Additionally, patients with anatomical abnormalities of the vagina that preclude the proper insertion or absorption of the vaginal insert are excluded.\n* Any condition contraindicating vaginal ultrasound and\u002For vaginal oocyte retrieval.These include: active pelvic inflammatory disease (PID), acute vaginal or cervical infection, or presence of pelvic malignancies. Patients with significant anatomical distortions or vascular anomalies in the pelvic region that, in the investigator's opinion, would make oocyte retrieval technically unfeasible or pose an unacceptable risk of hemorrhage or injury to adjacent organs, are also excluded.\n* Use of hormonal contraceptives (oral, patch, or ring) or GnRH analogues within the month preceding the study. Note: Participants who have discontinued these or other prohibited medications for a period of at least 30 days are eligible for rescreening starting at Visit 1.\n* Participation in any other ongoing clinical trial or use of investigational drugs within the last 30 days.","FEMALE","18 Years","33 Years",{"count":21,"type":22},10,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The goal of this clinical trial is to learn whether the sudden administration of vaginal micronized progesterone during the late follicular phase can trigger an LH surge and reactivation of oocyte meiosis in healthy oocyte donors aged 18 to 33 undergoing a mild ovarian stimulation cycle. The main question it aims to answer is:\n\n* Does progesterone administered in the late follicular phase induce an LH surge and subsequent oocyte meiosis reactivation?\n\nParticipants will:\n\n* Undergo a mild ovarian stimulation with 75 IU of follitropn alfa\n* Start vaginal micronized progesterone (400 mg every 12 hours) once at least one follicle reaches 15 mm\n* Have blood samples collected to measure hormone levels before and after progesterone administration\n* Undergo oocyte retrieval 35-36 hours after the progesterone trigger\n\nThis is a low-intervention, single-center pilot study including approximately 10 oocyte donors.",[28,29,30,31,32],"Ovulation","Ovarian Function","Assisted Reproductive Treatments","Oocyte Maturation","Hormonal Response",[34,35,36,31,37,38,39,40,41,42],"Trigger","Oocyte Donation","Progesterone","Luteinizing Hormone","LH Surge","Oocyte Retrieval","Oocyte Meiosis","Late Follicular Phase","Endocrinological profile","NOT_YET_RECRUITING","2026-06-02",{"date":46,"type":47},"2026-06-04","ACTUAL",{"date":49,"type":22},"2026-07",{"date":51,"type":22},"2026-08",{"name":53,"class":54},"Instituto Valenciano de Infertilidade de Lisboa","NETWORK",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":64,"sex":17,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":70,"conditions":71,"keywords":79,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":55},"100612012","smartphone-vs-manual-interpretation-of-biomarkers-for-ovulation-and-luteal-phase-detection-smom-study-100612012","NCT07248046","Smartphone vs Manual Interpretation of Biomarkers for Ovulation and Luteal Phase Detection (SMOM Study)","Comparing Cervical Mucus, PDG, LH, and Basal Body Temperature Combinations for Ovulation and Luteal Phase Identification Using the Premom Smartphone App Versus User-Read Test Results: A Prospective Observational Study","SMOM","Inclusion Criteria:\n\n* Female, aged 16 to 45\n* Natural menstrual cycles equal or less than 35 days\n* Off hormonal contraception for more than 3 months\n* Current user of the Premom App\n* Willing to track cervical mucus, LH, PDG, and BBT for 3 full cycles\n* Lives within 50 km of study site in the Ottawa region\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* Current hormonal therapy or contraception\n* Known anovulatory disorders, e.g., Polycystic Ovary Syndrome, hypothalamic amenorrhea.\n* Very irregular or absent cycles\n* Not using the Premom App\n* Unable or unwilling to complete tracking or provide consent",true,"16 Years","45 Years",{"count":68,"type":22},30,"OBSERVATIONAL","This study will compare different combinations of fertility signs (cervical mucus (CM), luteinizing hormone \\[LH\\], pregnanediol glucuronide \\[PDG\\], and basal body temperature \\[BBT\\]) to determine which are most reliable for identifying ovulation and luteal phase length. Thirty existing Premom App users will track daily observations for three menstrual cycles. Participants will record mucus, perform urine tests, upload test strip photos to the Premom App, and measure BBT. Both participant readings and AI-assisted app readings will be analyzed. The main goal is to find which marker pairings give the most accurate picture of ovulation timing and luteal phase length. Secondary goals include understanding ease of use, the number of tests required, and whether the app improves accuracy.",[72,73,74,75,76,77,28,78,36],"Fertility","Mobile Applications","Artifical Intelligence","Cervical Mucus","Body Temperature","Luteinizing Hormone (LH)","Menstrual Cycle",[28,80,78,72,75,37,81,36,82,83,84,73,85,86,87,88,89,90,91,92],"Luteal Phase","Pregnanediol Glucuronide","Basal Body Temperature","Female Reproductive Physiology","Fertility Awareness-Based Methods","Smartphone App","Artificial Intelligence","Self-Testing","Home Diagnostic Tests","Observational Study","Prospective Studies","Digital Health","Women's Health","RECRUITING","2026-01-10",{"date":96,"type":47},"2026-01-13",{"date":98,"type":22},"2026-01-15",{"date":100,"type":22},"2026-11-15",{"name":102,"class":103},"Bruyère Health Research Institute.","OTHER",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":64,"sex":110,"minAge":18,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":113,"conditions":114,"keywords":121,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":55},"100377597","apple-womens-health-study-100377597","NCT04196595","Apple Women's Health Study","Inclusion Criteria:\n\n* Have menstruated at least once\n* Be at least 18 years old (at least 19 years old in Alabama and Nebraska, at least 21 years old in Puerto Rico)\n* Live in the United States of America\n* Be comfortable communicating in written and spoken English\n* Have installed the Apple Research app on your iPhone\n* Not share your iCloud account or iPhone with anyone else\n* Be willing and able to provide informed consent to participate in the study","ALL",{"count":112,"type":22},500000,"This is an observational longitudinal study to advance the understanding of menstrual cycle and gynecologic health conditions including PCOS, infertility and breast cancer.The study will be hosted within the Research app(available on App Store), which allows a user to find, enroll, and participate in Apple-supported health-related research studies.",[78,28,115,116,117,118,119,120],"Menstruation","Polycystic Ovary Syndrome","Infertility","Menopause","Reproduction","Reproductive Health",[115,78,28,116,117,118,119,120],"2024-07-01",{"date":124,"type":47},"2024-07-03",{"date":126,"type":47},"2019-11-14",{"date":128,"type":22},"2029-11",{"name":130,"class":131},"Apple Inc.","INDUSTRY"]